Cancer Family
Pancreaticobiliary Neoplasm
CI-CAN-00000309Explore in graph →
Non-malignant1,204 active trials11 approved drugs92 evidence items
- NCIt
- C223357
Loading cancer entity…
Cancer Family
CI-CAN-00000309Explore in graph →
Clinical trials
5,004 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04111172 | A Vaccine (Ad5.F35-hGCC-PADRE) for the Treatment of Gastrointestinal Adenocarcinoma | suspended | Phase 2 | 48 | Thomas Jefferson UniversityOTHER | 1 | Sep 14, 2026 | clinicaltrials |
| NCT06050252 | Testing the Combination of the Anticancer Drug Durvalumab With Chemotherapy (Gemcitabine and Cisplatin) at Improving Outcomes for High-Risk Resectable Liver Cancer Before Surgery | suspended | Phase 2 | 27 | National Cancer Institute (NCI)NIH | 1 | Sep 4, 2026 |
| clinicaltrials |
| NCT06202066 | Temozolomide and Survivin Long Peptide Vaccine (SurVaxM) for the Treatment of Patients With Progressing Metastatic Neuroendocrine Carcinomas | suspended | Phase 2 | 60 | Roswell Park Cancer InstituteOTHER | 1 | Aug 20, 2026 | clinicaltrials |
| NCT05494697 | Ampligen Combined With SOC Versus SOC Alone Following First-Line Therapy in Subjects With LAPC | suspended | Phase 2 | 90 | AIM ImmunoTech Inc.INDUSTRY | 1 | Aug 19, 2026 | clinicaltrials |
| NCT07377526 | TROP2 CAREngineered Cord Blood-Derived NK Cells + Belzutifan In Pancreatic Cancer | suspended | Phase 1 / Phase 2 | 37 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 31, 2026 | clinicaltrials |
| NCT05419479 | Switch Maintenance in Pancreatic | suspended | Phase 1 / Phase 2 | 46 | James Cleary, MD, PhDOTHER | 1 | Jun 4, 2026 | clinicaltrials |
| NCT03417921 | A Study of ABTL0812 in Pancreatic Cancer(Pancreatic) | suspended | Phase 1 / Phase 2 | 60 | Ability Pharmaceuticals SLINDUSTRY | 1 | Oct 1, 2025 | clinicaltrials |
| NCT06199882 | SBRT Sequential Surufatinib Combined With Immunotherapy for Biliary Tract Carcinoma | suspended | Phase 2 | 34 | Zhejiang Cancer HospitalOTHER | 1 | Oct 15, 2024 | clinicaltrials |
| NCT04090463 | IORT on Borderline Resectable Pancreatic Cancer(PancFORT) | suspended | Phase 2 | 100 | Universita di VeronaOTHER | 1 | May 7, 2024 | clinicaltrials |
| NCT03610100 | Acelarin First Line Randomised Pancreatic Study(ACELARATE) | suspended | Phase 2 / Phase 3 | 328 | The Clatterbridge Cancer Centre NHS Foundation TrustOTHER | 1 | Oct 29, 2019 | clinicaltrials |
| NCT03779100 | Lenvatinib Plus PD-1 Antibody for Unresectable ICC | suspended | Phase 2 | 25 | Shi MingOTHER | 1 | Jan 28, 2019 | clinicaltrials |
| NCT00637364 | High Intensity Focused Ultrasound Tumor Treatment for Pancreatic Cancer Pain(HIFU Pancreas) | suspended | Phase 1 / Phase 2 | 5 | CMED HIFU Development CorporationINDUSTRY | 1 | Jan 13, 2009 | clinicaltrials |
| NCT00536770 | A Study of Gemcitabine ± Erlotinib and DN-101 Versus Gemcitabine ± Erlotinib and Placebo in Patients With Advanced Pancreatic Cancer | suspended | Phase 2 | 132 | NovaceaINDUSTRY | 1 | Nov 6, 2007 | clinicaltrials |
| NCT00209677 | Phase I/II Study of Oral S-1 Plus Gemcitabine in Patients With Metastatic Pancreatic Cancer | suspended | Phase 1 / Phase 2 | 40 | Hokkaido Gastrointestinal Cancer Study GroupOTHER | 1 | Nov 1, 2007 | clinicaltrials |
Data updated 16 days agoSource updated Sep 14, 2026source: clinicaltrials